Copyright Reports & Markets. All rights reserved.

Global Neutropenia Biologic Drug Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Filgrastim
    • 1.3.3 Pegfilgrastim
    • 1.3.4 Lenograstim
    • 1.3.5 Lipegfilgrastim
    • 1.3.6 Sargramostim
  • 1.4 Market by Application
    • 1.4.1 Global Neutropenia Biologic Drug Treatment Market Share by Application: 2020 VS 2026
    • 1.4.2 Retail Pharmacies
    • 1.4.3 Hospital Pharmacies
    • 1.4.4 Online Pharmacies
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2015-2026)
  • 2.2 Neutropenia Biologic Drug Treatment Growth Trends by Regions
    • 2.2.1 Neutropenia Biologic Drug Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Neutropenia Biologic Drug Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Neutropenia Biologic Drug Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Neutropenia Biologic Drug Treatment Industry Dynamic
    • 2.3.1 Neutropenia Biologic Drug Treatment Market Trends
    • 2.3.2 Neutropenia Biologic Drug Treatment Market Drivers
    • 2.3.3 Neutropenia Biologic Drug Treatment Market Challenges
    • 2.3.4 Neutropenia Biologic Drug Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Neutropenia Biologic Drug Treatment Players by Market Size
    • 3.1.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Neutropenia Biologic Drug Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Neutropenia Biologic Drug Treatment Revenue
  • 3.4 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio
    • 3.4.1 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Neutropenia Biologic Drug Treatment Revenue in 2019
  • 3.5 Key Players Neutropenia Biologic Drug Treatment Area Served
  • 3.6 Key Players Neutropenia Biologic Drug Treatment Product Solution and Service
  • 3.7 Date of Enter into Neutropenia Biologic Drug Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Neutropenia Biologic Drug Treatment Breakdown Data by Type

  • 4.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2021-2026)

5 Neutropenia Biologic Drug Treatment Breakdown Data by Application

  • 5.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Neutropenia Biologic Drug Treatment Market Size (2015-2026)
  • 6.2 North America Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
  • 6.3 North America Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
  • 6.4 North America Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Neutropenia Biologic Drug Treatment Market Size (2015-2026)
  • 7.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size (2015-2026)
  • 8.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Neutropenia Biologic Drug Treatment Market Size (2015-2026)
  • 9.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
  • 9.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
  • 9.4 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2015-2026)
  • 10.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 Teva Pharmaceutical
    • 11.1.1 Teva Pharmaceutical Company Details
    • 11.1.2 Teva Pharmaceutical Business Overview
    • 11.1.3 Teva Pharmaceutical Neutropenia Biologic Drug Treatment Introduction
    • 11.1.4 Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020))
    • 11.1.5 Teva Pharmaceutical Recent Development
  • 11.2 Amgen
    • 11.2.1 Amgen Company Details
    • 11.2.2 Amgen Business Overview
    • 11.2.3 Amgen Neutropenia Biologic Drug Treatment Introduction
    • 11.2.4 Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.2.5 Amgen Recent Development
  • 11.3 Sanofi
    • 11.3.1 Sanofi Company Details
    • 11.3.2 Sanofi Business Overview
    • 11.3.3 Sanofi Neutropenia Biologic Drug Treatment Introduction
    • 11.3.4 Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.3.5 Sanofi Recent Development
  • 11.4 Mylan(Fulphila)
    • 11.4.1 Mylan(Fulphila) Company Details
    • 11.4.2 Mylan(Fulphila) Business Overview
    • 11.4.3 Mylan(Fulphila) Neutropenia Biologic Drug Treatment Introduction
    • 11.4.4 Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.4.5 Mylan(Fulphila) Recent Development
  • 11.5 Kyowa Kirin
    • 11.5.1 Kyowa Kirin Company Details
    • 11.5.2 Kyowa Kirin Business Overview
    • 11.5.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Introduction
    • 11.5.4 Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.5.5 Kyowa Kirin Recent Development
  • 11.6 Novartis
    • 11.6.1 Novartis Company Details
    • 11.6.2 Novartis Business Overview
    • 11.6.3 Novartis Neutropenia Biologic Drug Treatment Introduction
    • 11.6.4 Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.6.5 Novartis Recent Development
  • 11.7 Spectrum Pharmaceuticals
    • 11.7.1 Spectrum Pharmaceuticals Company Details
    • 11.7.2 Spectrum Pharmaceuticals Business Overview
    • 11.7.3 Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
    • 11.7.4 Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.7.5 Spectrum Pharmaceuticals Recent Development
  • 11.8 Pfizer
    • 11.8.1 Pfizer Company Details
    • 11.8.2 Pfizer Business Overview
    • 11.8.3 Pfizer Neutropenia Biologic Drug Treatment Introduction
    • 11.8.4 Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.8.5 Pfizer Recent Development
  • 11.9 Baxter International
    • 11.9.1 Baxter International Company Details
    • 11.9.2 Baxter International Business Overview
    • 11.9.3 Baxter International Neutropenia Biologic Drug Treatment Introduction
    • 11.9.4 Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.9.5 Baxter International Recent Development
  • 11.10 Partner Therapeutics(Leukine)
    • 11.10.1 Partner Therapeutics(Leukine) Company Details
    • 11.10.2 Partner Therapeutics(Leukine) Business Overview
    • 11.10.3 Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Introduction
    • 11.10.4 Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 11.10.5 Partner Therapeutics(Leukine) Recent Development
  • 11.11 BeyondSpring Pharmaceuticals
    • 10.11.1 BeyondSpring Pharmaceuticals Company Details
    • 10.11.2 BeyondSpring Pharmaceuticals Business Overview
    • 10.11.3 BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
    • 10.11.4 BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 10.11.5 BeyondSpring Pharmaceuticals Recent Development
  • 11.12 Cellerant Therapeutics
    • 10.12.1 Cellerant Therapeutics Company Details
    • 10.12.2 Cellerant Therapeutics Business Overview
    • 10.12.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Introduction
    • 10.12.4 Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 10.12.5 Cellerant Therapeutics Recent Development
  • 11.13 Enzychem Lifesciences Corporation
    • 10.13.1 Enzychem Lifesciences Corporation Company Details
    • 10.13.2 Enzychem Lifesciences Corporation Business Overview
    • 10.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Introduction
    • 10.13.4 Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 10.13.5 Enzychem Lifesciences Corporation Recent Development
  • 11.14 Myelo Therapeutics
    • 10.14.1 Myelo Therapeutics Company Details
    • 10.14.2 Myelo Therapeutics Business Overview
    • 10.14.3 Myelo Therapeutics Neutropenia Biologic Drug Treatment Introduction
    • 10.14.4 Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 10.14.5 Myelo Therapeutics Recent Development
  • 11.15 Generon
    • 10.15.1 Generon Company Details
    • 10.15.2 Generon Business Overview
    • 10.15.3 Generon Neutropenia Biologic Drug Treatment Introduction
    • 10.15.4 Generon Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
    • 10.15.5 Generon Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Neutropenia Biologic Drug Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neutropenia Biologic Drug Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    By Drug Type
    Filgrastim
    Pegfilgrastim
    Lenograstim
    Lipegfilgrastim
    Sargramostim
    By Treatment Type
    Antibiotic Drugs
    Granulocyte-Colony-Stimulating Factor (G-CSF)
    Antifungal Drugs
    Others

    Market segment by Application, split into
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

    Based on regional and country-level analysis, the Neutropenia Biologic Drug Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Neutropenia Biologic Drug Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Teva Pharmaceutical
    Amgen
    Sanofi
    Mylan(Fulphila)
    Kyowa Kirin
    Novartis
    Spectrum Pharmaceuticals
    Pfizer
    Baxter International
    Partner Therapeutics(Leukine)
    BeyondSpring Pharmaceuticals
    Cellerant Therapeutics
    Enzychem Lifesciences Corporation
    Myelo Therapeutics

    Buy now